A form of diabetes that quietly affected some of the world’s poorest communities for generations has finally been given its own name and place in the medical playbook. Type 5 diabetes, once buried under vague labels and misdiagnoses, is now officially recognized as a distinct disease that behaves differently from the better known types 1 and 2. That shift is more than a technicality, because it forces health systems to confront how chronic malnutrition and poverty can literally rewire human metabolism.
I see this recognition as a turning point that links cutting edge endocrinology with basic questions of food security and justice. By carving out Type 5 diabetes as its own category, researchers and global health leaders are acknowledging that millions of lean, undernourished people were never just “atypical type 2” cases, but patients with a specific condition that demands tailored treatment, new research funding and, ultimately, political will.
How Type 5 diabetes finally got a name
For decades, clinicians in low income regions described a puzzling pattern: young, thin adults with a history of severe childhood hunger arriving with dangerously high blood sugar, but not fitting the classic profiles of autoimmune type 1 or obesity linked type 2 diabetes. Earlier this year, that pattern was formally codified when international experts agreed to classify this malnutrition related diabetes as Type 5 diabetes, a move that pulls it out of the shadows of older, confusing labels. The new terminology replaces the older term malnutrition related diabetes mellitus, or MRDM, and signals that this is not a historical curiosity but a current public health problem.
The road to recognition was long. Although case descriptions stretch back more than 70 years, the condition remained marginal in global guidelines and funding priorities. That changed when detailed metabolic studies showed that these patients have a distinct pattern of insulin production and sensitivity, and when advocates argued that a unique label would unlock better surveillance and care. By naming Type 5 diabetes explicitly, organizations are acknowledging that the disease is driven by chronic undernutrition, especially in childhood, and that it cannot be fully understood through the lens used for type 1, type 2, gestational diabetes or rarer genetic forms.
From MRDM to Type 5: a 70 year journey
The story of Type 5 diabetes begins with MRDM, a term clinicians used for lean patients whose diabetes seemed rooted in deprivation rather than excess. Historical reports from tropical regions described young adults with a background of severe childhood hunger, pancreatic damage and brittle blood sugar control, but the label MRDM never translated into clear treatment algorithms or large scale research. According to the International Diabetes Federation, this entity has been observed for over 70 years, yet it was largely overlooked in global health discussions, which focused instead on rising obesity and type 2 diabetes in wealthier and urban populations.
That neglect had consequences. Without a defined category, people with MRDM were often misclassified as having type 1 or type 2 diabetes, which meant they were slotted into treatment plans that did not match their physiology or life circumstances. The rebranding of MRDM as Type 5 diabetes is more than a cosmetic change, because it embeds the condition within the standard list of diabetes types and signals that it deserves the same level of scientific scrutiny. It also reflects a growing consensus that chronic malnutrition is not just a background risk factor but a central driver of this disease process.
What makes Type 5 diabetes biologically distinct
Clinically, Type 5 diabetes stands apart from the better known forms because it combines features that at first glance seem contradictory. Patients are typically lean, often with a history of stunting or underweight in childhood, yet they present with severe hyperglycemia and complications that resemble long standing diabetes. Metabolic studies show that their pancreas can still produce insulin, but not in sufficient amounts, and that the remaining beta cells may be damaged by years of nutritional stress. As one analysis put it, Type 5 diabetes stands apart from types 1 and 2, gestational diabetes, or forms linked to pregnancy or the immune system, because its roots lie in early life deprivation rather than autoimmunity or lifestyle related insulin resistance.
That distinct biology creates a tight therapeutic window. If clinicians assume these patients are classic type 1 cases and push insulin doses too high, they risk dangerous hypoglycemia in people who may already struggle to access regular meals. If they treat them like typical type 2 patients and rely mainly on oral drugs, blood sugar may remain uncontrolled because the damaged pancreas cannot respond adequately. Educational resources on Symptoms and Diagnosis emphasize that these individuals often fail to produce adequate insulin despite being thin, which means treatment has to be carefully titrated and supported by nutrition rather than copied from protocols designed for overnourished populations.
Who is affected, and where
Type 5 diabetes is not evenly distributed across the globe. It primarily affects people who experienced chronic undernutrition in childhood, especially in low and middle income countries where food insecurity, infections and limited health care intersect. The International Diabetes Federation notes that the condition primarily affects people in resource constrained settings, where access to both adequate calories and diabetes care is limited. Many of the documented cases come from rural areas in Asia and Africa, where diets are dominated by low protein staples and where children may endure repeated bouts of illness that further sap their nutritional reserves.
Research teams have highlighted that malnutrition related diabetes is seen mainly in lean individuals, often young adults, who grew up in environments marked by food scarcity and poverty. One group based in BRONX linked Malnutrition related diabetes to populations mainly in Asia and Africa, underscoring that this is not a rare anomaly but a pattern that tracks with global inequities. The International Diabetes Federation estimates that the number of people affected may rival or exceed some better known infectious diseases, yet many remain undiagnosed or misclassified because health workers are not trained to recognize Type 5 diabetes as a separate entity.
Why recognition in 2025 changes the stakes
The formal naming of Type 5 diabetes in 2025 did not happen in a vacuum. Earlier this year, the International Diabetes Federation used its World Diabetes Congress in Bangkok to spotlight the condition and to argue that it deserves dedicated research and policy attention. At the recent gathering in Thailand, the organization’s leadership announced a new initiative focused on this entity, signaling that Type 5 diabetes is now part of the mainstream conversation rather than a footnote. The decision to highlight the condition at the World Diabetes Congress in Bangkok reflects a broader shift toward acknowledging that diabetes in low and middle income countries does not always follow the patterns seen in wealthier nations.
Recognition also came through formal classification decisions. In January 2025, MRDM was designated as a distinct form of diabetes, now referred to as Type 5, at a major international meeting. Reports note that In January 2025, MRDM was officially recognized at the World Diabetes Congress 2025 in Bangkok, a decision that effectively rewrote the global taxonomy of the disease. That move has practical implications, because it opens the door for specific diagnostic codes, targeted clinical trials and funding streams that were previously unavailable for a condition that lacked a clear label.
Inside the new Type 5 diabetes working group
To turn recognition into action, the International Diabetes Federation has created a dedicated working group focused on Type 5 diabetes. The group’s mandate is to map the burden of disease, refine diagnostic criteria and develop treatment guidelines that reflect the realities of low resource settings. According to the federation, the initiative was launched at the World Diabetes Congress in Bangkok as part of a broader effort to address diabetes in low and middle income countries, often abbreviated as LMICs. The announcement of this new Type 5 diabetes working group underscores that global leaders now see malnutrition related diabetes as a priority rather than a niche concern.
The working group is expected to draw on clinicians and researchers from regions where Type 5 diabetes is most common, ensuring that guidelines are grounded in lived experience rather than extrapolated from high income settings. Its agenda includes standardizing how cases are identified, improving access to appropriate laboratory tests and integrating nutrition support into diabetes care. By coordinating efforts across countries, the group aims to generate robust data on prevalence and outcomes, which in turn can inform national health plans and donor priorities. In practical terms, that could mean more training for frontline health workers, better supply chains for insulin and oral drugs, and stronger links between diabetes clinics and food assistance programs.
Symptoms, diagnosis and how it differs from types 1 and 2
From a patient’s perspective, Type 5 diabetes can look deceptively familiar. People often present with classic symptoms of high blood sugar, such as excessive thirst, frequent urination, weight loss and fatigue. What sets them apart is their body type and history: they are usually lean or even underweight, with a background of chronic undernutrition or stunting, rather than the overweight profile often associated with type 2 diabetes. Educational materials on Symptoms and Diagnosis stress that these patients may have residual insulin production but still fail to produce adequate insulin for their needs, which can lead to severe hyperglycemia despite a low calorie diet.
Diagnostically, the challenge is to distinguish Type 5 diabetes from types 1 and 2 so that treatment can be tailored appropriately. Unlike Type 1, which is driven by autoimmune destruction of beta cells, and type 2, which is dominated by insulin resistance in the context of excess weight, Type 5 diabetes seems to stem from malnutrition that damages the pancreas and alters metabolism. Patient guides explain that, unlike Type 1 and Type 2, this form is closely tied to early life deprivation, and that recognizing this history is key to making the right diagnosis. One overview framed it as a condition where Unlike Type 1 and Type 2 diabetes, the disease is driven by long term undernutrition rather than autoimmunity or lifestyle related insulin resistance, which means clinicians must ask about childhood diet and growth patterns, not just current weight.
Treatment dilemmas and the “fine line” for doctors
Once Type 5 diabetes is identified, managing it becomes a delicate balancing act. The distinct metabolic profile means that doctors have to tread a fine line between providing enough insulin to control blood sugar and avoiding hypoglycemia in patients whose food intake may be unpredictable. Reports on the condition note that the Distinct New Type of Diabetes Is Officially recognized as requiring careful titration of therapy, because standard dosing algorithms based on body weight or carbohydrate intake may not apply cleanly to undernourished individuals. Clinicians must also consider coexisting deficiencies, such as low protein or micronutrient intake, which can influence how the body responds to medication.
Some experts argue that Type 5 diabetes “requires its own type of treatment,” a phrase that captures both the scientific and ethical stakes. Coverage of the condition has highlighted that new type diabetes requires tailored approaches that integrate nutrition support with pharmacologic therapy. That might include prioritizing access to regular meals, providing supplements to rebuild muscle and pancreatic function, and adjusting drug regimens to match the realities of rural life, where refrigeration for insulin and frequent glucose monitoring may be difficult. The goal is not only to lower blood sugar but to break the cycle in which poverty, hunger and inadequate care reinforce one another.
Why this matters beyond the clinic
The recognition of Type 5 diabetes also forces a broader reckoning with how societies allocate resources. One analysis pointed out that Malnutrition related diabetes is more common than tuberculosis and nearly as common as HIV and AIDS, yet it has received a fraction of the attention and funding. That comparison is stark, because tuberculosis, HIV and AIDS have long been seen as emblematic diseases of poverty that mobilized global campaigns and billions of dollars in aid. If Type 5 diabetes is operating at a similar scale, then ignoring it amounts to a policy choice that leaves millions of vulnerable people without adequate support.
The stakes are not confined to low income countries. In the United States, for example, Nearly 39 m people already live with diabetes, and food insecurity remains a persistent problem in many communities. While Type 5 diabetes as currently defined is most common in settings of severe early life malnutrition, the underlying lesson is that nutrition across the life course shapes metabolic health in profound ways. As I see it, recognizing this new category should prompt wealthier countries to look more closely at how childhood hunger, structural racism and unequal access to healthy food might be creating their own, less visible metabolic fault lines.
How media and patient education are catching up
Public awareness of Type 5 diabetes is still in its infancy, but coverage is starting to catch up with the science. Health explainers now describe how Diabetes Has Officially Been Recognized as a new type and outline what makes it different from other forms. These pieces often emphasize that You do not need to be overweight to develop serious blood sugar problems, and that a history of childhood malnutrition can leave a metabolic scar that surfaces years later. They also stress the importance of listening to patients who do not fit textbook profiles, rather than forcing them into existing categories that do not quite match their experience.
Specialist blogs and educational platforms are also stepping in to translate emerging research into practical guidance. One New Class of Diabetes Emerges overview traces the history of Type 5 diabetes back to early descriptions in The Lancet by Hugh Jones P, then walks through current thinking on diagnosis and management. Another resource titled Global Impact and Future Directions highlights the need for more data, better training and integrated nutrition programs. As these materials circulate, they help clinicians, patients and policymakers understand that Type 5 diabetes is not an obscure curiosity but a lens on how early life hardship can shape health for decades.
The global push after decades of being ignored
For people living with Type 5 diabetes, the new label comes after a long period of confusion and neglect. Coverage of the condition has noted that There is Now a Type 5 Diabetes And Doctors Say It has Been Ignored For Decades, a blunt acknowledgment that health systems failed to see what was in front of them. After decades of confusion, Type 5 diabetes is finally being recognized as a distinct entity, and in 2025, the International Diabetes Federation moved to formally acknowledge it as well. That recognition is the product of a global push by clinicians who had watched too many patients fall through the cracks because their disease did not fit existing boxes.
Scientific explainers have echoed that sense of overdue attention. One piece framed the development by noting that a Distinct New Type of Diabetes Is Officially recognized, while another summarized the shift under the heading Distinct New Type of Diabetes Is Officially Recognized, underscoring how unusual it is for an entirely new class of such a common disease to be carved out in the twenty first century. A separate explainer on What Type 5 diabetes is described how this Newly recognized form of the disease gets its name and noted that it remained largely overlooked until now. Taken together, these narratives suggest that the recognition of Type 5 diabetes is not just a scientific milestone but a moral one, because it finally gives a name and a framework to people whose illness was long dismissed as an anomaly.
What comes next for research and policy
Looking ahead, the key question is whether recognition will translate into sustained investment. The International Diabetes Federation has already signaled that it wants to quantify the burden of Type 5 diabetes and integrate it into national diabetes strategies, particularly in low and middle income countries. Its overview of Type 5 diabetes stresses that better data are needed for the millions affected globally, and that health systems must adapt screening and treatment protocols to account for this distinct form. That will likely require new funding streams, partnerships between endocrinologists and nutrition programs, and a willingness to rethink how success is measured in diabetes care.
At the same time, researchers are calling for more basic science to unravel exactly how chronic undernutrition reshapes the pancreas and other organs. Some are exploring whether early nutritional interventions could prevent Type 5 diabetes in high risk children, while others are testing drug regimens tailored to the unique metabolic profile of these patients. As I see it, the emergence of Type 5 diabetes as a recognized category is a reminder that medicine is still catching up with the full consequences of poverty and inequality. The challenge now is to ensure that this new label becomes a tool for change rather than just another line in a classification manual.
More from MorningOverview